Abionic Scores $21m To Push Through 5-Min Sepsis Test
Swiss diagnostics developer Abionic has scored CHF20m ($21m) in Series C financing from a syndicate of high-net-worth individuals to kickstart a multinational study into the efficacy of its Pancreatic Stone Protein (PSP) test for rapid sepsis risk assessment and management.
You may also be interested in...
Swiss start-up Abionic has CE marked rapid tests for sepsis and iron deficiency, designed to run on its diagnostics platform abioSCOPE. The new sepsis test is based on a new biomarker PSP which has shown to be superior to current tests in detecting this life threatening condition early.
At the LSX World Congress in London, leaders from Medtronic, Johnson & Johnson and Olympus discussed the evolving medtech mergers and acquisitions landscape, the big opportunity in robotic surgery and the impacts on innovation of the forthcoming EU Medical Device Regulation.
Israeli start-up Serenno Medical is targeting 2020 for US FDA clearance and launch of its Sentinel device for early detection and prevention of acute kidney injury, a condition that affects 19 million patients worldwide every year.